CTOs on the Move


 
STIMIT`s proprietary technology enables extended local delivery of cancer immunotherapy in the context of tumor resection, the standard of care for most patients with solid tumors. Concentrating and retaining the action of potent immunomodulators locally dramatically improves the efficacy and safety of these compounds relative to administration in solution, whether via intravenous or even intratumoral injection.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

STIMIT raised $20.6M on 12/03/2020

Similar Companies

Y-mAbs Therapeutics

YmAbs has a powerful set of capabilities for the development of biologics. Our product development team includes some of the most talented and experienced professionals in the antibody industry.

Remix Therapeutics

Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.

M Silicon Biosystems

Solutions for isolation, recovery, and analysis of intact, individual rare cells. Single "cell sorter"

Nacalai USA

Nacalai USA is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kronos Bio

Kronos Bio is clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) through which they drive oncogenic activity.